Learn more about the aspects of pharmaceutical pricing  

The Aspects of Pharmaceutical Pricing
- State-of-the-art pricing knowledge –

February 2012
The business model of the pharmaceutical industry with a third party and often public payer has always puzzled people. The patients who benefit from treatment with a medicine pay part or even nothing of the cost. Within this constrained environment, pricing is more important than ever. To set a price too high may block market access, to set a price too low will leave money on the table.

A current analysis of McKinsey shows that over the years, real price increases – rewarding past innovation and changes in ways for treating patients – have been the main driver of the pharmaceutical industry’s development. Less attention has been paid to managing the cost base. Lowering the profit margins will suggest a need for new business models.
If you want to learn more about the aspects of pharmaceutical pricing, you can attend this interactive course, organized by the European Pricing Platform. This course addresses the critical policy issues in developing the best pricing strategy for your pharmaceutical products. Attend this unique opportunity to hear best practices from Raf De Wilde, a Healthcare Pricing and Market Access Expert.

Practical information
Venue: Husa President Park Hotel, Brussels (Belgium)
Date: 13th and 14th of March 2012
Trainer: Raf De Wilde – Associate Vice President – United BioSource Corporation
Do you want more information about this practical and interactive training? Please visit, http://www.pricingplatform.eu/site/public/trainings_detail.asp?id=131 or contact me directly to request further detailed information or to require group discounts
joyce.verfaillie@pricingplatform.eu

The EPP is the -not-for-profit- on- and offline meeting place for pricing and profit optimization decision makers in a wide range of industries. Interactive sharing, collecting and developing pricing knowledge is the key.

Sources: European Pricing Platform – www.pricingplatform.eu

McKinsey https://www.mckinseyquarterly.com/Health_Care/Pharmaceuticals/A_wake-up_call_for_Big_Pharma_2897